Advancing ACE723, a GPC3 Targeting Dual-Payload ADC, to the Clinic
11:45 am - Wednesday 10th March 2027
- Building the ACE723 preclinical package with anti-tumour potency and NHP toxicology
- Developing support to the ACE723 programme with transition into first-inhuman studies
- Outlining the Phase I clinical design and progress for ACE723 in GPC3-expressing tumours